Literature DB >> 9144391

Screening of inhibitors of HIV-1 protease using an Escherichia coli cell assay.

J Büttner1, K Dornmair, H J Schramm.   

Abstract

To evaluate the available peptidic and pseudopeptidic inhibitors of HIV protease for their possible in vivo activity, a screening test using Escherichia coli was established. E. coli cells carrying the plasmid pET9c-PR containing the gene for HIV-1 protease under the control of a T7-promotor are grown in the absence and in the presence of inhibitors. The action of the toxic protease produced by the cells is counteracted by the inhibitors. Provided sufficient membrane permeability of the inhibitors exists, this results in accelerated cell growth. From the peptides known to be active in an in-vitro enzyme test, most compounds inhibit HIV protease only to a limited degree in this test. However, two short peptides (Ac-Ser-Tyr-Glu-Leu and Lys-Ile-Ser-Tyr-Asp-Tyr) protect cell growth to an considerabe extent, thus indicating that they reach the E. coli cytosol and there block HIV protease. Two pseudopeptides known to be very potent in the enzyme test (SDZ PRI 053 and CIBA 61755) also inhibit HIV-1 protease strongly in this cell growth test.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144391     DOI: 10.1006/bbrc.1997.6403

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells.

Authors:  Rahul Sampath; Nathan W Cummins; Sekar Natesampillai; Gary D Bren; Thomas D Chung; Jason Baker; Keith Henry; Amélie Pagliuzza; Andrew D Badley
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.